GSTP1 and mesothelioma: The cPVP prodrug, incorporating valproic acid and phenyl butyrate as axial ligands, demonstrated triple-action efficacy by simultaneously inhibiting lysine deacetylases (KDACs), suppressing nucleotide excision repair (NER), and downregulating glutathione-S-transferase π (GSTπ) expression in mesothelioma models [109].